(NASDAQ: DRRX) Durect's forecast annual revenue growth rate of 41.04% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Durect's revenue in 2024 is $8,548,000.On average, 3 Wall Street analysts forecast DRRX's revenue for 2024 to be $330,626,306, with the lowest DRRX revenue forecast at $248,287,848, and the highest DRRX revenue forecast at $472,057,271. On average, 1 Wall Street analysts forecast DRRX's revenue for 2025 to be $559,889,097, with the lowest DRRX revenue forecast at $559,889,097, and the highest DRRX revenue forecast at $559,889,097.
In 2026, DRRX is forecast to generate $734,000,951 in revenue, with the lowest revenue forecast at $734,000,951 and the highest revenue forecast at $734,000,951.